
Background Immune checkpoint inhibitors (ICIs) and targeted therapies like BRAF and MEK inhibitors have improved advanced melanoma outcomes but can cause ocular adverse events that threaten vision if not caught early. While such eye issues have been noted for specific therapies, comparisons across these treatments in real-world populations are limited. Objectives To compare ocular adverse-event phenotypes and associated serious outcomes among ICIs, BRAF inhibitors, and MEK inhibitors in patients with melanoma using a real-world pharmacovigilance database. Design Retrospective pharmacovigilance study utilizing the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Methods FAERS reports from January 2018 to September 2025 analyzed for melanoma-related reports with ocular adverse events. Reports were filtered by indication and deduplicated. Drug exposures grouped into ICIs, BRAF inhibitors, and MEK inhibitors. The main analysis classified reports by the primary suspect drug, with a sensitivity analysis excluding reports with multiple agents. Ocular phenotypes and serious outcomes were assessed using reporting odds ratios (RORs), with p-values adjusted via the Benjamini-Hochberg method. Results A total of 31,482 melanoma-related adverse-event reports were identified, with 2,633 (8.4%) containing at least one ocular adverse event. The primary class-specific cohort included 2,463 reports, and the single-agent cohort included 705 reports. ICIs showed higher reporting of inflammatory and optic nerve events, BRAF inhibitors reported more retinal, choroid, vitreous, and visual disturbances, and MEK inhibitors reported more visual disturbances with fewer inflammatory and optic nerve events. ICIs also showed higher serious outcomes and hospitalization, while BRAF and MEK inhibitors had lower reporting of serious outcomes. The strict analysis confirmed several class-specific patterns while reducing others after excluding reports with multiple agents. Conclusions Ocular adverse events associated with systemic melanoma therapies demonstrate distinct and comparatively different toxicity patterns across therapeutic classes in real-world data. By directly comparing ICIs, BRAF inhibitors, and MEK inhibitors within a unified pharmacovigilance framework, this study highlights class-specific differences in both phenotype and severity, providing a foundation for mechanism-informed monitoring strategies and multidisciplinary care.
Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase to reduce cholesterol but can cause muscle-related side effects. A rare severe form, immune-mediated necrotizing myopathy (IMNM), is an autoimmune condition characterized by proximal weakness, very high creatine kinase (CK) levels, and muscle necrosis with minimal inflammation. We report a 73-year-old man on long-term rosuvastatin who developed acute proximal muscle weakness, dark urine, and acute kidney injury (AKI) shortly after receiving goserelin. Laboratory tests showed severe rhabdomyolysis with markedly elevated CK and renal failure requiring hemodialysis. Muscle biopsy and serology confirmed anti-HMG-CoA reductase (anti-HMGCR) IMNM with complement-mediated muscle injury. Treatment with high-dose corticosteroids led to gradual improvement in strength, although residual renal impairment persisted at discharge. We describe a rare presentation of anti-HMGCR IMNM with fulminant rhabdomyolysis temporally associated with initiation of goserelin in a patient on chronic rosuvastatin therapy. The findings raise the possibility that gonadotropin-releasing hormone (GnRH) agonists may act as additional immunomodulatory triggers in genetically or immunologically predisposed individuals. Early recognition and prompt immunosuppressive treatment are essential to prevent irreversible organ damage and improve outcomes.
Background Adequate medication knowledge of patients is critical for medication safety, particularly among psychiatric patients exposed to complex pharmacotherapy. However, data on patients treated in psychiatric day hospital settings are limited. Objectives This study aimed to assess medication knowledge and identify factors associated with knowledge gaps in this population. Design Cross-sectional observational study. Methods A total of 101 patients from a psychiatric day hospital were included. Medication knowledge was assessed using a structured interviewer-administered questionnaire covering drug name, indication, dosage and administration schedule (possible score range: 0–6). Group differences and associations were analysed using Mann–Whitney U tests, Kruskal–Wallis tests and Spearman correlations. Results The median medication knowledge score was 4.3 (interquartile range (IQR) 3.0–5.8). A moderate negative correlation was observed between the number of medications taken and knowledge (ρ = −0.404, p < 0.001). Knowledge was not associated with sex (p = 0.29) or age (ρ = −0.093, p = 0.353). Knowledge differed significantly across drug classes (p < 0.001), being highest for nervous system drugs. Discrepancies between prescribed and reported medication were frequent, with 29 patients reporting 44 additional undocumented medications. The internet (31.7%) and medical specialists (30.7%) were the most reported sources of medication-related information. Conclusion Medication knowledge among psychiatric day hospital patients varied considerably and was lower among patients receiving a higher number of medications. Frequent discrepancies between documented and patient-reported medication use were observed, indicating a potential risk for unsafe medication use. In addition, insufficient medication knowledge may represent a clinically relevant risk factor for medication-related problems. Targeted, patient-centred education strategies should be prioritized to improve medication safety in this setting.
Background Potentially inappropriate medication (PIM) prescribing in older adults contributes to adverse drug events and healthcare utilization. Synchronous specialist teleconsultation may expand access to medication review, but its association with prescribing appropriateness across multiple specialties remains uncertain. Objectives To assess changes in documented and specialist-recommended PIM regimens immediately following specialist teleconsultation. Design Retrospective, paired pre-post observational cohort study. Methods We analyzed 14,995 completed teleconsultation encounters involving 13,580 unique adults aged 60 years or older in the Brazilian TeleAMES program from March 2020 through February 2025. Each encounter contributed a medication regimen documented by the primary care clinician before consultation and a regimen recommended by the specialist after consultation. PIMs were classified according to the 2023 American Geriatrics Society (AGS) Beers Criteria. The primary outcome was the encounter-level proportion with at least one PIM. Paired binary comparisons and generalized estimating equation (GEE) models with patient-level clustering were used. Regression models included time (before versus after) as the sole predictor and were not adjusted for baseline covariates. Results The proportion of encounters with at least one PIM decreased from 32.7% to 29.6%, an absolute reduction of 3.1 percentage points and a relative reduction of 9.5% (p = 0.03). The mean PIM count also decreased (incidence rate ratio [IRR], 0.971; 95% confidence interval [CI], 0.952-0.991; p = 0.004). Count rates declined for drug-disease contraindications (IRR, 0.631; 95% CI, 0.601-0.663; p < 0.001), high-risk drug-drug interactions (IRR, 0.766; 95% CI, 0.672-0.873; p < 0.001), and medications requiring renal dose adjustment (IRR, 0.929; 95% CI, 0.901-0.958; p < 0.001). The largest specialty-specific absolute reductions were observed in Cardiology (34.2% to 21.4%) and Endocrinology (38.1% to 22.3%). Conclusion Immediately after specialist teleconsultation, specialist-recommended regimens contained fewer PIMs, particularly within high-risk prescribing domains. Because post-consultation lists represented recommendations rather than confirmed dispensing, implementation, or medication use, and because no concurrent control group was available, these findings indicate an association with documented prescribing changes rather than a causal reduction in medication exposure.
The ethical and risk-based implementation and monitoring of artificial intelligence (AI) and machine learning within pharmacovigilance systems presents significant challenges, made more complicated by evolving regulatory landscapes. A pharmacovigilance organization requires a robust governance framework for ensuring patient safety and maintaining regulatory compliance as technology rapidly advances. This perspective review proposes a control plan as a structured, living document solution for effectively governing AI models, including statistical based machine learning, large language models, and generative AI. It integrates existing principles and requirements by suggesting critical elements such as performance parameters for the model and its infrastructure, criteria for successful human monitoring, triggers for model modification, identified risks with mitigation strategies, and appropriate explainability of AI outcomes. The objective of a control plan is to ensure transparency to regulators, safeguard patient safety, and build confidence in the organization’s risk-based management approach. The proposed AI control plan provides a structured approach to governing and monitoring AI systems within pharmacovigilance, enhancing operational transparency and regulatory compliance. It consolidates various established best practices and regulatory considerations into a unified framework. The adaptive nature of a control plan is crucial for responsible and effective AI utilization as technology and regulations evolve.